Notice: This company has been marked as potentially delisted and may not be actively trading. Acorda Therapeutics (ACOR) News Today Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Acorda: I didn't know Tony Yang was wanted in ChinaOctober 9, 2024 | msn.comMultiple Sclerosis Therapeutic Market to hit USD 38.1 billion by 2032, says Global Market Insights Inc.September 30, 2024 | finance.yahoo.comAcorda amid POGO allegations: I love country, PNPSeptember 25, 2024 | msn.comAcorda: I did not accept money from GuoSeptember 25, 2024 | msn.comIntranasal Drug Delivery Research Report 2024: Global Market to Reach $92.6 Billion by 2030 - Controlled Release Technology is the New Buzz WordSeptember 12, 2024 | uk.finance.yahoo.comMultiple Sclerosis Drugs Market Outlook and Strategic Business Report 2024-2030: Increased Awareness and Diagnosis Rates Boosting Treatment AdoptionAugust 26, 2024 | sg.finance.yahoo.comEssential cancer treatment company files Chapter 11 bankruptcyMay 16, 2024 | msn.comAcorda Therapeutics Announces Delisting from NasdaqApril 15, 2024 | businesswire.comAcorda Therapeutics Inc.April 14, 2024 | wsj.comPearl River-based Acorda Therapeutics to close; 97 jobs impactedApril 8, 2024 | msn.comRiskiest Junk Bonds Shunned in Europe on Rising Risk of DefaultApril 6, 2024 | finance.yahoo.comAcorda Therapeutics Announces Nasdaq Delisting NotificationApril 3, 2024 | businesswire.comAcorda Therapeutics Files for Chapter 11 BankruptcyApril 3, 2024 | baystreet.caCrude Oil Surges Over 1%; US Factory Orders Increase In FebruaryApril 2, 2024 | msn.comWhy Acorda Therapeutics Stock Is Down Nearly 90%April 2, 2024 | benzinga.comTrading was temporarily halted for "ACOR" at 11:04 AM with a stated reason of "LULD pause."April 2, 2024 | marketbeat.comTrading was temporarily halted for "ACOR" at 11:04 AM with a stated reason of "LULD pause."April 2, 2024 | marketbeat.comTrading was temporarily halted for "ACOR" at 10:04 AM with a stated reason of "LULD pause."April 2, 2024 | marketbeat.comTrading was temporarily halted for "ACOR" at 10:04 AM with a stated reason of "LULD pause."April 2, 2024 | marketbeat.comTrading was temporarily halted for "ACOR" at 10:04 AM with a stated reason of "LULD pause."April 2, 2024 | marketbeat.comWhy Is Acorda Therapeutics (ACOR) Stock Down 72% Today?April 2, 2024 | investorplace.comNorth American Morning Briefing: Stocks Seen Weaker as Doubts Over Fed Cuts MountApril 2, 2024 | morningstar.comMerz Therapeutics: Merz Enters Asset Purchase Agreement With a US-Based Biotech CompanyApril 2, 2024 | finanznachrichten.deAcorda retires from PNP after 3 months of extended serviceApril 1, 2024 | msn.comRetired PNP chief Acorda: I did my bestApril 1, 2024 | msn.comStocks to Watch: PVH, Canoo, Acorda TherapeuticsApril 1, 2024 | marketwatch.comAcorda Therapeutics shares sink nearly 40% after bankruptcy filingApril 1, 2024 | msn.comAcorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024April 1, 2024 | finance.yahoo.comAcorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024March 26, 2024 | finance.yahoo.comKlick Health Launches First AI Social Media Comment Moderator for Life Sciences IndustryMarch 11, 2024 | finance.yahoo.com3 Biotech Stocks to Watch in March for SuccessFebruary 28, 2024 | stocknews.comAcorda Therapeutics Stock (NASDAQ:ACOR), Short Interest ReportFebruary 23, 2024 | benzinga.comAcorda Therapeutics Stock (NASDAQ:ACOR) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comAcorda: No policy vs. TikTok use in PNPFebruary 20, 2024 | msn.comAcorda: PNP can’t interfere with people’s initiative for Charter changeFebruary 6, 2024 | msn.comTeodoro, Acorda nix Mindanao separation from PhilippinesFebruary 5, 2024 | msn.comPNP chief Acorda tells ranks: Ignore ‘political noise’January 31, 2024 | msn.comDementia and Movement Disorder Treatment Market to Grow by USD 8.55 billion, Market Share, Trends, and Growth Analysis - TechnavioJanuary 29, 2024 | finance.yahoo.comAcorda Therapeutics To Regain Worldwide Commercialization Rights To FAMPYRAJanuary 11, 2024 | markets.businessinsider.com3 Biotech Stocks to Keep an Eye on in 2024January 10, 2024 | stocknews.comAcorda files raps vs person spreading false info in viral vlogJanuary 8, 2024 | msn.comAcorda slams vlogger in 'disinformation' driveJanuary 8, 2024 | msn.comAcorda files cybercrime raps vs person spreading false info in a vlogJanuary 8, 2024 | msn.comAcorda eyes Pinoy apps vs cybercrimesJanuary 7, 2024 | msn.comAcorda Therapeutics Inc ACORJanuary 6, 2024 | morningstar.comAshvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical OperationsJanuary 4, 2024 | finance.yahoo.comModerna (MRNA) and Acorda Therapeutics (ACOR): Buy, Hold, or Sell in 2024?December 18, 2023 | stocknews.comAcorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The IndustryDecember 18, 2023 | finance.yahoo.com3 Biotech Stocks Flashing Year-End 'Buy' Signals"December 15, 2023 | stocknews.com3 Safe Biotech Stocks to Buy This WeekNovember 24, 2023 | stocknews.com Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address 3 CENT Crypto to Explode December 16th? (Ad)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career… #1 FREE Crypto for 2025 ACOR Media Mentions By Week ACOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACOR News Sentiment▼0.000.65▲Average Medical News Sentiment ACOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACOR Articles This Week▼01▲ACOR Articles Average Week Get Acorda Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MTEM News Today AMGN News Today GILD News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today NBIX News Today INCY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACOR) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe Next Big Thing in AI: Musk’s Secret SupplierWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredApple feeling the heat from NvidiaNvidia has moved on to the next frontier of AI it intends to dominate. And we believe the three companies p...Weiss Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredDeadline Approaching! A new system to collect up to $4,243 in monthly dividendsI've just released updated details on a new system for collecting steady dividend income each and every month....Investors Alley | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acorda Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acorda Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
